Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), CervoMed (CRVO) and Teladoc (TDOC)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inventiva (IVA – Research Report), CervoMed (CRVO – Research Report) and Teladoc (TDOC – Research Report) with bullish sentiments.

Inventiva (IVA)

Canaccord Genuity analyst Edward Nash maintained a Buy rating on Inventiva on April 5 and set a price target of $20.00. The company’s shares closed last Friday at $3.78.

According to TipRanks.com, Nash is a 3-star analyst with an average return of 1.1% and a 37.5% success rate. Nash covers the Healthcare sector, focusing on stocks such as Rani Therapeutics Holdings, Madrigal Pharmaceuticals, and Cardiol Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Inventiva with a $20.25 average price target, which is a 442.9% upside from current levels. In a report issued on March 28, LifeSci Capital also maintained a Buy rating on the stock with a $14.00 price target.

See today’s best-performing stocks on TipRanks >>

CervoMed (CRVO)

In a report issued on April 5, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on CervoMed, with a price target of $65.00. The company’s shares closed last Friday at $20.50.

According to TipRanks.com, Kulkarni is a 4-star analyst with an average return of 5.2% and a 42.7% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, ACADIA Pharmaceuticals, and Voyager Therapeutics.

Currently, the analyst consensus on CervoMed is a Moderate Buy with an average price target of $65.00.

Teladoc (TDOC)

Canaccord Genuity analyst Richard Close maintained a Buy rating on Teladoc on April 5 and set a price target of $28.00. The company’s shares closed last Friday at $14.49, close to its 52-week low of $13.59.

According to TipRanks.com, Close is a 4-star analyst with an average return of 7.7% and a 49.6% success rate. Close covers the Healthcare sector, focusing on stocks such as Clover Health Investments, Privia Health Group, and Health Catalyst.

Currently, the analyst consensus on Teladoc is a Moderate Buy with an average price target of $20.56, implying a 46.4% upside from current levels. In a report released today, Barclays also assigned a Buy rating to the stock with a $25.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on IVA:

• Inventiva’s Latest Move: Issuing Royalty Certificates That Could Dilute Lanifibranor Earnings
• Inventiva SA ADR Announces Optimistic 2023 Results
• Inventiva’s LEGEND Trial Shows Promising Results
• Inventiva announces LEGEND trial meets primary endpoint
• Inventiva lifts pause on screening for NATiV3 clinical trial